Bioverativ Therapeutics, Inc./swedish Orphan Biovitrum Ab (publ) competitive analysis

Explore patent oppositions filed by Bioverativ Therapeutics, Inc./swedish Orphan Biovitrum Ab (publ) against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 3, 2026
Patent NumberTitleApplicantOpposition Date
Proteolytically Cleavable Fusion Protein Comprising A Blood Coagulation FactorCSL BEHRING GMBHDec 13, 2019

Latest PTAB cases involving Bioverativ Therapeutics, Inc./swedish Orphan Biovitrum Ab (publ)

Discover the latest PTAB cases involving Bioverativ Therapeutics, Inc./swedish Orphan Biovitrum Ab (publ), highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Bioverativ Therapeutics, Inc./swedish Orphan Biovitrum Ab (publ) with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIOVERATIV THERAPEUTICS, INC./SWEDISH ORPHAN BIOVITRUM AB (PUBL)1 - - -
CSL BEHRING GMBH744 -